GWS
XBI icon

Greykasell Wealth Strategies’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Greykasell Wealth Strategies’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$36.4K Hold
285
– – 0.01% 273
2025
Q4 		$34.8K Buy
+285
New +$32.7K 0.01% 267

Other funds holding XBI

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Greykasell Wealth Strategies's XBI Position: Q1 2026 in Review

Greykasell Wealth Strategies held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q1 2026 at 285 shares worth $36.4K. The position accounts for 0.01% of the portfolio, ranked #273.

Greykasell Wealth Strategies first reported a position in XBI in Q4 2025 and has held it in 2 quarters since. 815 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • Greykasell Wealth Strategies held 285 shares of State Street SPDR S&P Biotech ETF worth $36.4K as of Q1 2026.
  • Greykasell Wealth Strategies left its State Street SPDR S&P Biotech ETF share count unchanged in Q1 2026.
  • State Street SPDR S&P Biotech ETF made up 0.01% of Greykasell Wealth Strategies's portfolio in Q1 2026, its #273 holding.
  • Greykasell Wealth Strategies first reported a position in State Street SPDR S&P Biotech ETF in Q4 2025 and has held it in 2 quarters since.
  • 815 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Greykasell Wealth Strategies's 13F filing for Q1 2026, filed 7 May 2026.